272 related articles for article (PubMed ID: 25930155)
1. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of bleeding episodes in patients with von Willebrand's disease.
Federici AB
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s26-32. PubMed ID: 19105507
[TBL] [Abstract][Full Text] [Related]
3. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
Holm E; Abshire TC; Bowen J; Álvarez MT; Bolton-Maggs P; Carcao M; Federici AB; Gill JC; Halimeh S; Kempton C; Key NS; Kouides P; Lail A; Landorph A; Leebeek F; Makris M; Mannucci P; Mauser-Bunschoten EP; Nugent D; Valentino LA; Winikoff R; Berntorp E
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):383-8. PubMed ID: 25688461
[TBL] [Abstract][Full Text] [Related]
4. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).
Abshire TC; Federici AB; Alvárez MT; Bowen J; Carcao MD; Cox Gill J; Key NS; Kouides PA; Kurnik K; Lail AE; Leebeek FW; Makris M; Mannucci PM; Winikoff R; Berntorp E;
Haemophilia; 2013 Jan; 19(1):76-81. PubMed ID: 22823000
[TBL] [Abstract][Full Text] [Related]
6. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
7. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
Franchini M
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s33-8. PubMed ID: 19105508
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
9. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.
Mannucci PM; Chediak J; Hanna W; Byrnes J; Ledford M; Ewenstein BM; Retzios AD; Kapelan BA; Schwartz RS; Kessler C;
Blood; 2002 Jan; 99(2):450-6. PubMed ID: 11781224
[TBL] [Abstract][Full Text] [Related]
10. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
11. How I treat patients with von Willebrand disease.
Mannucci PM
Blood; 2001 Apr; 97(7):1915-9. PubMed ID: 11264151
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis in von Willebrand Disease: Coming of Age?
Saccullo G; Makris M
Semin Thromb Hemost; 2016 Jul; 42(5):498-506. PubMed ID: 27253087
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
Miesbach W; Berntorp E
Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
[TBL] [Abstract][Full Text] [Related]
16. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
17. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
19. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis in von Willebrand disease.
Franchini M; Targher G; Lippi G
Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
